{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-048539","form_type":"8-K","ticker":"DCTH","cik":"0000872912","company_name":"DELCATH SYSTEMS, INC.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.416538+00:00","generated_at":"2026-05-17T00:47:27.229007+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Delcath Q3 2025 revenue $20.6M (+84% YoY); net income $0.8M; FY revenue guidance $83-85M","bullets":["Q3 total revenue $20.6M (+84% YoY); HEPZATO revenue $19.3M, CHEMOSAT $1.3M.","Net income $0.8M (down from $1.9M YoY) due to higher R&D ($8M vs $3.9M) and SG&A ($10.3M vs $7M).","Non-GAAP adjusted EBITDA $5.3M (vs $1M YoY); cash & investments $88.9M, no debt.","FY 2025 guidance: revenue $83-85M (150% volume growth), gross margins 85-87%, positive EBITDA & cash flow each quarter.","Clinical progress: Phase 2 CRC trial dosed first patient; CHOPIN trial showed improved survival; 25 active U.S. centers."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-048539","json":"https://secwatch.observer/filing/0001628280-25-048539.json","markdown":"https://secwatch.observer/filing/0001628280-25-048539.md","text":"https://secwatch.observer/filing/0001628280-25-048539.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872912/000162828025048539/0001628280-25-048539-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872912/000162828025048539/dcth-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:47:27.229007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}